Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$83.61 USD

83.61
5,456,718

+0.57 (0.69%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $83.61 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Gilead, Galapagos Announce Positive Data on Inflammatory Drug

Gilead (GILD) and Galapagos announce positive data on filgotinib for the treatment of ulcerative colitis.

These 4 High Earnings Yield Stocks are Hot Investment Picks

Earnings yield has an edge over P/E ratio as it can be used to compare a stock with not just other stocks but also with fixed income securities.

Glaxo's Long-Acting HIV Injection Effective Than Daily Pills

Glaxo's (GSK) long-acting injectable formulation of cabotegravir dosed every two months shows higher efficacy than daily oral pills.

Ritujay Ghosh headshot

5 Biotech Stocks in Focus as Race for Coronavirus Vaccine Heats Up

Drugmakers and biotech companies are initiating development of drugs, vaccines and therapies for COVID-19 and substantial progress has been made over the past month.

The Zacks Analyst Blog Highlights: JPMorgan Chase, AbbVie, Royal Dutch Shell, Gilead Sciences and Anthem

The Zacks Analyst Blog Highlights: JPMorgan Chase, AbbVie, Royal Dutch Shell, Gilead Sciences and Anthem

Sheraz Mian headshot

Top Stock Reports for JPMorgan, AbbVie & Royal Dutch Shell

Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase (JPM), AbbVie (ABBV) and Royal Dutch Shell (RDS.A).

Pluralsight, Stanley Black Decker, Gilead, Regeneron and GlaxoSmithKline as Zacks Bull and Bear of the Day

Pluralsight, Stanley Black Decker, Gilead, Regeneron and GlaxoSmithKline as Zacks Bull and Bear of the Day

Agenus' (AGEN) IND for iNKT Therapy Gets FDA Acceptance

The FDA clears Agenus' (AGEN) IND application for allogeneic iNKT therapy, agenT-797, which is being developed to treat cancer as well as the deadly COVID-19 pandemic.

Zacks.com headshot

Biotech Companies Lead Search for Coronavirus Vaccine: 4 Winners

Although a vaccine is yet to be developed, many companies have already started ramping up manufacturing process of the experimental vaccine candidates they are working on.

Intercept's (ICPT) Q1 Earnings and Revenues Beat Estimates

Intercept (ICPT) reports better-than-expected results for the first quarter of 2020 on solid Ocaliva sales.

Sanghamitra Saha headshot

6 Leveraged ETFs Up At Least 25% Last Week

Oil, tech and biotech caused a rally in the leveraged ETF space last week.

Sweta Jaiswal, FRM headshot

Are Biotech ETFs in Trouble as Coronavirus Dims Guidance?

Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their Q1 earnings releases amid the coronavirus crisis.

Sanghamitra Saha headshot

6 ETF Areas Beating S&P 500 in 2020

The S&P 500 is down 10.8% this year, after a massive recovery in April. But these ETF areas have beaten the S&P 500 this year.

Ligand (LGND) Beats on Q1 Earnings & Sales, Raises View

Ligand (LGND) reports higher-than-expected first-quarter 2020 earnings and revenues.

The Zacks Analyst Blog Highlights: Gilead Sciences, Pfizer, Regeneron Pharmaceuticals, Moderna and Sanofi

The Zacks Analyst Blog Highlights: Gilead Sciences, Pfizer, Regeneron Pharmaceuticals, Moderna and Sanofi

Neena Mishra headshot

Biotech ETFs Poised to Benefit From Coronavirus

Rising investor interest in coronavirus related stocks will benefit these ETFs

GILD vs. ILMN: Which Stock Should Value Investors Buy Now?

GILD vs. ILMN: Which Stock Is the Better Value Option?

Is Gilead Sciences, Inc. (GILD) Stock Outpacing Its Medical Peers This Year?

Is (GILD) Outperforming Other Medical Stocks This Year?

5 Stocks to Buy as Coronavirus Vaccine in Human Trails Ramp Up

As drug makers race to develop vaccine to fight coronavirus, we shortlist five stocks that are poised to grow on progress in clinical trials.

Sanghamitra Saha headshot

3 Sector ETFs Gaining Momentum in May

After a wobbly start, Wall Street steadied in May. These sector ETFs contributed the most in Wall Street recovery on Monday.

Sanghamitra Saha headshot

Top ETF Stories of April Likely to Hit Headlines Again in May

Energy, gold, online retail and biotech were the most-discussed ETF areas in April and could continue to be so in May.

Remdesivir Gets Emergency Approval: What's In Store for Gilead?

In a short span of time, Gilead's Remdesivir has been successful in treating some coronavirus patients. But will this give a boost to the pharmaceutical giant?

Gilead (GILD) Q1 Earnings Top, Coronavirus Candidate in Focus

Gilead (GILD) reports better-than-expected results for the first quarter but the uncertain outlook for the year dampens investors' hopes.

Sanghamitra Saha headshot

ETF Strategies to Follow With U.S. Economy Slowly Reopening

As the U.S. economy is gradually reopening, these investment areas should perform well.